Brokers Issue Forecasts for X4 Pharmaceuticals, Inc.’s Q3 2024 Earnings (NASDAQ:XFOR)

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Stock analysts at Brookline Capital Management cut their Q3 2024 earnings estimates for X4 Pharmaceuticals in a research note issued to investors on Monday, April 29th. Brookline Capital Management analyst L. Cann now forecasts that the company will post earnings of ($0.19) per share for the quarter, down from their prior forecast of ($0.15). The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.51) per share. Brookline Capital Management also issued estimates for X4 Pharmaceuticals’ Q4 2024 earnings at ($0.13) EPS, FY2024 earnings at ($0.66) EPS and FY2025 earnings at ($0.06) EPS.

Separately, HC Wainwright boosted their target price on shares of X4 Pharmaceuticals from $3.00 to $5.00 and gave the stock a “buy” rating in a report on Tuesday.

X4 Pharmaceuticals Stock Up 6.5 %

XFOR stock opened at $1.15 on Thursday. X4 Pharmaceuticals has a twelve month low of $0.57 and a twelve month high of $2.58. The company has a market cap of $193.13 million, a price-to-earnings ratio of -1.92 and a beta of 0.51. The company has a quick ratio of 5.34, a current ratio of 5.34 and a debt-to-equity ratio of 1.07. The business has a 50 day moving average price of $1.16 and a two-hundred day moving average price of $0.93.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings results on Thursday, March 21st. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.05.

Institutional Investors Weigh In On X4 Pharmaceuticals

Several hedge funds have recently bought and sold shares of XFOR. SG Americas Securities LLC acquired a new position in shares of X4 Pharmaceuticals in the third quarter valued at approximately $37,000. Barclays PLC lifted its holdings in shares of X4 Pharmaceuticals by 334.8% during the third quarter. Barclays PLC now owns 382,134 shares of the company’s stock worth $417,000 after buying an additional 294,255 shares in the last quarter. GSA Capital Partners LLP bought a new stake in shares of X4 Pharmaceuticals in the third quarter valued at about $678,000. Kingdon Capital Management L.L.C. increased its position in X4 Pharmaceuticals by 76.0% during the fourth quarter. Kingdon Capital Management L.L.C. now owns 3,473,683 shares of the company’s stock worth $2,913,000 after acquiring an additional 1,500,000 shares during the period. Finally, Stonepine Capital Management LLC raised its stake in X4 Pharmaceuticals by 14.5% in the 3rd quarter. Stonepine Capital Management LLC now owns 5,273,685 shares of the company’s stock worth $5,748,000 after purchasing an additional 668,422 shares in the last quarter. 72.03% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at X4 Pharmaceuticals

In other news, CFO Adam S. Mostafa sold 52,500 shares of X4 Pharmaceuticals stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $0.88, for a total transaction of $46,200.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, CFO Adam S. Mostafa sold 27,721 shares of the stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $1.01, for a total value of $27,998.21. Following the transaction, the chief financial officer now directly owns 52,500 shares of the company’s stock, valued at $53,025. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Adam S. Mostafa sold 52,500 shares of X4 Pharmaceuticals stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $0.88, for a total transaction of $46,200.00. The disclosure for this sale can be found here. Insiders have sold 185,708 shares of company stock worth $170,428 over the last 90 days. Company insiders own 1.08% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.